Citius Pharmaceuticals, Inc. (CTXR)

NASDAQ: CTXR · IEX Real-Time Price · USD
0.777
+0.009 (1.18%)
At close: Mar 1, 2024, 4:00 PM
0.760
-0.017 (-2.19%)
After-hours: Mar 1, 2024, 7:59 PM EST
1.18%
Market Cap 123.68M
Revenue (ttm) n/a
Net Income (ttm) -39.33M
Shares Out 159.10M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE 1.29
Dividend n/a
Ex-Dividend Date n/a
Volume 326,319
Open 0.756
Previous Close 0.768
Day's Range 0.756 - 0.797
52-Week Range 0.600 - 1.710
Beta 1.43
Analysts Strong Buy
Price Target 4.00 (+414.54%)
Earnings Date Feb 14, 2024

About CTXR

Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 22
Stock Exchange NASDAQ
Ticker Symbol CTXR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for CTXR stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target
$4.0
(414.54% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement to Replace Expiring Prior Shelf Registration

CRANFORD, N.J. , Feb. 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerci...

6 days ago - PRNewsWire

Citius Pharmaceuticals to Participate in Upcoming BIO CEO and Sidoti Investor Conferences

CRANFORD, N.J. , Feb. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerci...

9 days ago - PRNewsWire

Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results and Provides Business Update

Resubmitted LYMPHIR™ Biologics License Application; awaiting PDUFA date Completed enrollment in the Mino-Lok® Pivotal Phase 3 trial CRANFORD, N.J. , Feb. 14, 2024 /PRNewswire/ -- Citius Pharmaceutical...

18 days ago - PRNewsWire

Citius Pharmaceuticals Resubmits the Biologics License Application of LYMPHIR™ (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

FDA acceptance of the completed resubmission package and issuance of a Prescription Drug User Fee Act (PDUFA) date is expected within 30 days of resubmission CRANFORD, N.J. , Feb. 13, 2024 /PRNewswire...

18 days ago - PRNewsWire

Citius Pharmaceuticals Announces Nomination of Pharmaceutical Executive Robert J. Smith to its Board of Directors

Independent Director nominee expected to be elected at Annual Shareholders' Meeting in March 2024 CRANFORD, N.J. , Jan. 23, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company"...

5 weeks ago - PRNewsWire

Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic to Salvage Catheters

Topline results expected 2Q 2024 Study enrolled a total of 241 patients; 109 catheter failures observed First-and-only antibiotic lock solution in development to salvage catheters in patients with CRB...

2 months ago - PRNewsWire

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update

Mino-Lok® Pivotal Phase 3 trial enrollment completed; topline data expected 2Q 2024 LYMPHIR™ BLA resubmission on track for early 2024 CRANFORD, N.J. , Jan. 2, 2024 /PRNewswire/ -- Citius Pharmaceutica...

2 months ago - PRNewsWire

Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023

CRANFORD, N.J. , Nov. 9, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company developing and commercializing first-in-class critica...

4 months ago - PRNewsWire

Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor

Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy alone by transiently depleting Tregs in the...

4 months ago - PRNewsWire

Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.

Citius Pharmaceuticals, Inc. to receive $675 million in equity of Citius Oncology, Inc. and retain approximately 90% majority control in publicly listed Citius Oncology, Inc. post transaction Transact...

4 months ago - PRNewsWire

Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023

CRANFORD, N.J. , Sept. 18, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerc...

5 months ago - PRNewsWire

Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir

CRANFORD, N.J. , Sept. 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) mourns the loss of longtime board member, Howard Safir, who passed away on Monda...

6 months ago - PRNewsWire

Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™

Resubmission to FDA planned for early 2024 CRANFORD, N.J. , Sept. 8, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) is pleased to announce the Company has...

6 months ago - PRNewsWire

Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023

CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerci...

6 months ago - PRNewsWire

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update

$33.3 million in cash and cash equivalents as of June 30, 2023; runway through August 2024 CRANFORD, N.J. , Aug. 14, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasd...

7 months ago - PRNewsWire

Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial

CRANFORD, N.J. , Aug. 10, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerci...

7 months ago - PRNewsWire

Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

No clinical efficacy or safety issues raised Citius committed to working toward approval CRANFORD, N.J. , July 29, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq...

7 months ago - PRNewsWire

Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes

CRANFORD, N.J. , June 26, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-c...

8 months ago - PRNewsWire

Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

CITI-002 provides a meaningful reduction in symptom severity when compared to individual components alone Dose for Phase 3 trial selected; Citius to schedule end of Phase 2 meeting with the FDA Trial ...

9 months ago - PRNewsWire

Citius Pharmaceuticals to Participate in Maxim Group's Virtual Healthcare Conference on June 21, 2023

CRANFORD, N.J. , June 13, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerci...

9 months ago - PRNewsWire

Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update

$29.1 million in cash and cash equivalents as of March 31, 2023; $15 million registered direct offering in May 2023 extends runway through May 2024 Halo-Lido Phase 2b trial completed with topline resu...

10 months ago - PRNewsWire

Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering

CRANFORD, N.J. , May 8, 2023 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commerciali...

10 months ago - PRNewsWire

Citius Pharmaceuticals Announces $15 Million Registered Direct Offering

CRANFORD, N.J. , May 4, 2023 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commerciali...

10 months ago - PRNewsWire

Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date

CRANFORD, N.J. , April 24, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commerc...

11 months ago - PRNewsWire

Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids

Topline Results anticipated by the end of Q2 2023 CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last p...

11 months ago - PRNewsWire